Medtronic has completed its acquisition of Twelve, which is a privately-held medical device company that is focused on the development of a transcatheter mitral valve implantation (TMVI) device. Sean Salmon, senior vice president and president, Coronary & Structural Heart, Medtronic, says: “This acquisition supports Medtronic’s therapy innovation strategy, as TMVI represents an important growth opportunity for our business. We look forward to welcoming the Twelve team to Medtronic to help deliver an exciting and differentiated therapy to patients.”
A press release reports that, in collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. It adds that the company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world. The Medtronic TMVI technology is not available for sale in any country.
